# Implantation or Injectable Dosage Form New Animal Drugs; Tilmicosin Phosphate Injection
> **Food and Drug Administration** · Final rule. · Published 1998-02-17 · Effective 1998-02-17 · 63 FR 7701
## Document
- **Document number:** 98-3897
- **Category:** other
- **Sub-agency:** Food and Drug Administration
- **Federal Register citation:** 63 FR 7701
- **CFR reference:** 21 CFR 522
- **Publication date:** 1998-02-17
- **Effective date:** 1998-02-17
## Abstract

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Elanco Animal Health, A Division of Eli Lilly and Co. The supplemental NADA provides for removal of the label warnings concerning subcutaneous use of tilmicosin phosphate injection in preruminating (veal) calves. Removal of the warning is based on a tissue residue depletion study in calves less than 1 month of age.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/1998/02/17/98-3897/implantation-or-injectable-dosage-form-new-animal-drugs-tilmicosin-phosphate-injection)
---
*AI Analytics · CC0 1.0*